---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-026002"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2023-07-31T23:59:59+00:00"
generated_at: "2026-06-12T21:50:12.584136+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# MyMD announces positive Phase 2 topline results for MYMD-1 in sarcopenia/frailty

## Summary
- Study met primary endpoints: significantly reduced TNF-α (P=0.008), sTNFR1 (P=0.02), and IL-6 (P=0.03) levels.
- All pharmacokinetic and secondary safety/tolerability endpoints achieved; no treatment-related adverse events.
- Company to present data to FDA and intends to advance MYMD-1 into Phase 3 for sarcopenia.
- MYMD-1 is first oral TNF-α inhibitor candidate; potential first FDA-approved drug for sarcopenia if approved.

## SEC filing metadata
- accession: 0001493152-23-026002
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2023-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315223026002/0001493152-23-026002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315223026002/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-026002
- JSON: https://secwatch.observer/filing/0001493152-23-026002.json
- Plain text: https://secwatch.observer/filing/0001493152-23-026002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.